Concepts (166)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alcoholism | 14 | 2022 | 1109 | 1.520 |
Why?
|
| Substance-Related Disorders | 7 | 2022 | 1242 | 1.210 |
Why?
|
| Buprenorphine | 3 | 2015 | 67 | 1.210 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 3 | 2022 | 91 | 0.970 |
Why?
|
| Opioid-Related Disorders | 3 | 2015 | 298 | 0.950 |
Why?
|
| Analgesics, Opioid | 3 | 2015 | 498 | 0.880 |
Why?
|
| Paroxetine | 4 | 2013 | 28 | 0.880 |
Why?
|
| Naltrexone | 6 | 2020 | 195 | 0.820 |
Why?
|
| Anxiety Disorders | 4 | 2013 | 426 | 0.750 |
Why?
|
| Anxiety | 3 | 2013 | 422 | 0.670 |
Why?
|
| Ambulatory Care | 2 | 2019 | 340 | 0.630 |
Why?
|
| Program Development | 2 | 2017 | 240 | 0.620 |
Why?
|
| National Institutes of Health (U.S.) | 2 | 2017 | 109 | 0.600 |
Why?
|
| Alcohol-Related Disorders | 2 | 2009 | 95 | 0.580 |
Why?
|
| Patient Compliance | 2 | 2019 | 402 | 0.570 |
Why?
|
| Narcotic Antagonists | 4 | 2017 | 184 | 0.560 |
Why?
|
| Biomedical Research | 2 | 2017 | 310 | 0.550 |
Why?
|
| Phobic Disorders | 6 | 2013 | 227 | 0.540 |
Why?
|
| Opiate Substitution Treatment | 1 | 2015 | 57 | 0.490 |
Why?
|
| Withholding Treatment | 1 | 2014 | 35 | 0.490 |
Why?
|
| Patient Preference | 1 | 2015 | 57 | 0.480 |
Why?
|
| Antidepressive Agents, Second-Generation | 2 | 2013 | 54 | 0.480 |
Why?
|
| Behavior, Addictive | 1 | 2017 | 317 | 0.460 |
Why?
|
| Pharmacogenetics | 1 | 2014 | 47 | 0.450 |
Why?
|
| Social Behavior Disorders | 1 | 2013 | 16 | 0.440 |
Why?
|
| Substance Withdrawal Syndrome | 4 | 2021 | 435 | 0.410 |
Why?
|
| Nerve Net | 1 | 2014 | 181 | 0.400 |
Why?
|
| Psychiatry | 4 | 2022 | 112 | 0.390 |
Why?
|
| Catechol O-Methyltransferase | 2 | 2022 | 31 | 0.380 |
Why?
|
| Attitude | 1 | 2012 | 121 | 0.380 |
Why?
|
| Adult | 21 | 2022 | 21403 | 0.360 |
Why?
|
| Alcohol Drinking | 3 | 2018 | 805 | 0.350 |
Why?
|
| Comorbidity | 5 | 2021 | 1426 | 0.350 |
Why?
|
| Self Report | 1 | 2012 | 371 | 0.340 |
Why?
|
| Shyness | 1 | 2009 | 10 | 0.330 |
Why?
|
| Humans | 35 | 2022 | 68618 | 0.320 |
Why?
|
| Female | 24 | 2022 | 38074 | 0.300 |
Why?
|
| Male | 22 | 2022 | 37321 | 0.290 |
Why?
|
| Surgical Procedures, Operative | 1 | 2007 | 124 | 0.270 |
Why?
|
| Severity of Illness Index | 6 | 2019 | 1851 | 0.260 |
Why?
|
| Mass Screening | 1 | 2012 | 843 | 0.260 |
Why?
|
| Middle Aged | 14 | 2021 | 21147 | 0.260 |
Why?
|
| Anticonvulsants | 2 | 2005 | 223 | 0.250 |
Why?
|
| Pain, Postoperative | 1 | 2007 | 214 | 0.250 |
Why?
|
| Brain | 3 | 2017 | 2176 | 0.240 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2009 | 468 | 0.240 |
Why?
|
| gamma-Aminobutyric Acid | 2 | 2021 | 208 | 0.220 |
Why?
|
| Gyrus Cinguli | 2 | 2021 | 113 | 0.220 |
Why?
|
| Receptors, Opioid, mu | 2 | 2020 | 70 | 0.210 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2008 | 767 | 0.200 |
Why?
|
| Ethanol | 2 | 2022 | 893 | 0.190 |
Why?
|
| Double-Blind Method | 7 | 2021 | 1738 | 0.190 |
Why?
|
| Alcohol Deterrents | 3 | 2018 | 86 | 0.190 |
Why?
|
| Prevalence | 2 | 2019 | 1619 | 0.180 |
Why?
|
| Alcohol Abstinence | 1 | 2020 | 23 | 0.180 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 2 | 2013 | 151 | 0.180 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 1 | 2020 | 82 | 0.180 |
Why?
|
| Valproic Acid | 2 | 2014 | 93 | 0.170 |
Why?
|
| Excitatory Amino Acid Antagonists | 1 | 2020 | 128 | 0.170 |
Why?
|
| Glutamic Acid | 1 | 2021 | 332 | 0.150 |
Why?
|
| Internship and Residency | 2 | 2022 | 596 | 0.150 |
Why?
|
| Taurine | 2 | 2014 | 51 | 0.140 |
Why?
|
| Nicotine | 1 | 2018 | 350 | 0.120 |
Why?
|
| Students, Medical | 2 | 2014 | 210 | 0.120 |
Why?
|
| United States | 4 | 2017 | 7367 | 0.120 |
Why?
|
| Basal Ganglia Diseases | 1 | 1993 | 13 | 0.110 |
Why?
|
| Fluoxetine | 1 | 1993 | 40 | 0.110 |
Why?
|
| Retrospective Studies | 2 | 2019 | 7277 | 0.110 |
Why?
|
| Lithium | 1 | 1993 | 76 | 0.110 |
Why?
|
| Serotonin | 1 | 1993 | 144 | 0.110 |
Why?
|
| Aged | 4 | 2018 | 14862 | 0.110 |
Why?
|
| Treatment Outcome | 7 | 2020 | 7029 | 0.110 |
Why?
|
| Smoking | 2 | 2018 | 1452 | 0.110 |
Why?
|
| Neuroimaging | 1 | 2014 | 122 | 0.100 |
Why?
|
| Young Adult | 3 | 2018 | 5717 | 0.100 |
Why?
|
| Fellowships and Scholarships | 3 | 2022 | 127 | 0.100 |
Why?
|
| Data Collection | 2 | 2014 | 420 | 0.090 |
Why?
|
| Combined Modality Therapy | 1 | 2013 | 951 | 0.090 |
Why?
|
| Education | 1 | 2011 | 83 | 0.090 |
Why?
|
| Psychiatric Status Rating Scales | 2 | 2007 | 782 | 0.090 |
Why?
|
| Behavioral Medicine | 1 | 2010 | 23 | 0.090 |
Why?
|
| Research | 1 | 2011 | 214 | 0.080 |
Why?
|
| Adaptation, Psychological | 1 | 2013 | 447 | 0.080 |
Why?
|
| Sleep | 2 | 2022 | 263 | 0.080 |
Why?
|
| Surveys and Questionnaires | 2 | 2022 | 2800 | 0.080 |
Why?
|
| Substance Abuse Treatment Centers | 1 | 2008 | 71 | 0.080 |
Why?
|
| Inservice Training | 1 | 2008 | 68 | 0.070 |
Why?
|
| Administration, Sublingual | 1 | 2007 | 15 | 0.070 |
Why?
|
| Patient Participation | 1 | 2009 | 146 | 0.070 |
Why?
|
| Naloxone | 1 | 2007 | 56 | 0.070 |
Why?
|
| Follow-Up Studies | 2 | 2017 | 3259 | 0.070 |
Why?
|
| Placebos | 1 | 2007 | 195 | 0.070 |
Why?
|
| Community Health Services | 1 | 2008 | 141 | 0.070 |
Why?
|
| Time Factors | 1 | 2015 | 4655 | 0.070 |
Why?
|
| Mental Disorders | 1 | 2012 | 659 | 0.070 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 1 | 2007 | 257 | 0.070 |
Why?
|
| Pilot Projects | 2 | 2008 | 1342 | 0.060 |
Why?
|
| Self Administration | 1 | 2007 | 419 | 0.060 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2007 | 1745 | 0.060 |
Why?
|
| Carbamazepine | 1 | 2005 | 108 | 0.060 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2005 | 60 | 0.060 |
Why?
|
| Amines | 1 | 2005 | 98 | 0.060 |
Why?
|
| Secondary Prevention | 1 | 2005 | 291 | 0.060 |
Why?
|
| Catechol O-Methyltransferase Inhibitors | 1 | 2022 | 5 | 0.050 |
Why?
|
| Depressive Disorder, Major | 1 | 2007 | 439 | 0.050 |
Why?
|
| Actigraphy | 1 | 2022 | 28 | 0.050 |
Why?
|
| Recurrence | 2 | 2022 | 948 | 0.050 |
Why?
|
| Career Choice | 2 | 2014 | 98 | 0.050 |
Why?
|
| Proton Magnetic Resonance Spectroscopy | 1 | 2021 | 27 | 0.050 |
Why?
|
| Quality of Life | 1 | 2010 | 1515 | 0.050 |
Why?
|
| Depression | 1 | 2008 | 943 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2005 | 931 | 0.050 |
Why?
|
| Outpatients | 1 | 2021 | 127 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2017 | 2223 | 0.050 |
Why?
|
| Dopamine | 1 | 2022 | 474 | 0.040 |
Why?
|
| Bupropion | 1 | 2000 | 63 | 0.040 |
Why?
|
| Crying | 1 | 1999 | 6 | 0.040 |
Why?
|
| Maternal Behavior | 1 | 1999 | 29 | 0.040 |
Why?
|
| Clonazepam | 1 | 1998 | 6 | 0.040 |
Why?
|
| Genotype | 1 | 2020 | 786 | 0.040 |
Why?
|
| Sialoglycoproteins | 1 | 2018 | 24 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2020 | 627 | 0.040 |
Why?
|
| Transferrin | 1 | 2018 | 94 | 0.040 |
Why?
|
| Drug Interactions | 1 | 2018 | 289 | 0.040 |
Why?
|
| Pharmacogenomic Variants | 1 | 2017 | 15 | 0.040 |
Why?
|
| Survival | 1 | 1997 | 22 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2017 | 249 | 0.030 |
Why?
|
| Animals | 1 | 2014 | 20881 | 0.030 |
Why?
|
| Visual Perception | 1 | 2017 | 124 | 0.030 |
Why?
|
| Reward | 1 | 2017 | 201 | 0.030 |
Why?
|
| Brain Mapping | 1 | 2017 | 532 | 0.030 |
Why?
|
| Psychometrics | 1 | 1997 | 514 | 0.030 |
Why?
|
| Prefrontal Cortex | 1 | 1999 | 640 | 0.030 |
Why?
|
| Cues | 1 | 2017 | 654 | 0.030 |
Why?
|
| Biomarkers | 1 | 2018 | 1593 | 0.030 |
Why?
|
| Prognosis | 1 | 2017 | 2093 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 1993 | 649 | 0.020 |
Why?
|
| Disulfiram | 1 | 2011 | 22 | 0.020 |
Why?
|
| Off-Label Use | 1 | 2011 | 17 | 0.020 |
Why?
|
| Fructose | 1 | 2011 | 51 | 0.020 |
Why?
|
| Curriculum | 1 | 2014 | 575 | 0.020 |
Why?
|
| Depressive Disorder | 1 | 1993 | 621 | 0.020 |
Why?
|
| Quality Assurance, Health Care | 1 | 2010 | 177 | 0.020 |
Why?
|
| Internet | 1 | 2010 | 390 | 0.020 |
Why?
|
| Social Behavior | 1 | 2007 | 164 | 0.020 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 1997 | 1506 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2011 | 657 | 0.020 |
Why?
|
| Adolescent | 1 | 2018 | 8912 | 0.020 |
Why?
|
| South Carolina | 1 | 2011 | 2752 | 0.010 |
Why?
|
| Delayed-Action Preparations | 1 | 2000 | 120 | 0.010 |
Why?
|
| Object Attachment | 1 | 1999 | 20 | 0.010 |
Why?
|
| Mother-Child Relations | 1 | 1999 | 43 | 0.010 |
Why?
|
| Personality Inventory | 1 | 1998 | 197 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 1998 | 567 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 1999 | 652 | 0.010 |
Why?
|
| Neurosecretory Systems | 1 | 1996 | 21 | 0.010 |
Why?
|
| Area Under Curve | 1 | 1997 | 238 | 0.010 |
Why?
|
| Factor Analysis, Statistical | 1 | 1997 | 201 | 0.010 |
Why?
|
| Neurotransmitter Agents | 1 | 1996 | 102 | 0.010 |
Why?
|
| Panic Disorder | 1 | 1996 | 121 | 0.010 |
Why?
|
| Linear Models | 1 | 1997 | 521 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 1997 | 1040 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 1996 | 1140 | 0.010 |
Why?
|
| Infant, Newborn | 1 | 1999 | 2455 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 1997 | 1753 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 1997 | 2077 | 0.010 |
Why?
|